Source: Novartis and DNDi | Feb 25, 2020

Novartis and Drugs for Neglected Diseases initiative (DNDi) to collaborate on the development of a new oral drug to treat Visceral Leishmaniasis

Visceral leishmaniasis, also known as kala-azar, is the most serious form of leishmaniasis, causing fever, weight loss, spleen and liver enlargement, and if left untreated, death

LXE408 is a first-in-class compound, discovered at Novartis (https://www.Novartis.com/) with financial support from the Wellcome Trust; Novartis is responsible for completing Phase I clinical trials and has committed to maximizing access in endemic countries, once approved; DNDi (https://www.DNDi.org/) will lead Phase II and III clinical development, starting in India with…